Epidemiology and Burden of Pediatric Atopic Dermatitis in China.

IF 3.5 3区医学 Q1 DERMATOLOGY

Dermatology and Therapy Pub Date : 2025-06-01 Epub Date: 2025-04-17 DOI:10.1007/s13555-025-01403-4

Chien-Chia Chuang, Lydia Braham-Chaouche, Ryan Thomas, Tarek Mnif

{"title":"Epidemiology and Burden of Pediatric Atopic Dermatitis in China.","authors":"Chien-Chia Chuang, Lydia Braham-Chaouche, Ryan Thomas, Tarek Mnif","doi":"10.1007/s13555-025-01403-4","DOIUrl":null,"url":null,"abstract":"Introduction: We aimed to estimate the prevalence, severity, and burden of pediatric atopic dermatitis (AD) in China.Methods: EPI-CARE China was a cross-sectional online survey that assessed AD in the general pediatric populations (aged 0.5‒17 years) between 21 March 2021 and 5 April 2021 in China. Diagnosis of AD prevalence was based on both International Study of Asthma and Allergies in Childhood criteria and self-reported or parent-reported physician confirmation of ever having had AD. Severity (mild, moderate, and severe) in the preceding week was assessed by patient global assessment. Health-related quality of life (HRQoL) was assessed using established dermatology patient-reported outcomes tools (Infant Dermatitis Quality of Life and Children's Dermatology Life Quality Index). Outcomes included type 2 inflammatory comorbidities and itch, skin pain, and sleep disturbance in the previous 24 h (numeric rating scale [NRS]: 0-10 [no symptoms-worst symptoms]), stratified by age group (aged ≤ 5 years, 6-11 years, and 12-17 years).Results: In 7148 patients, AD prevalence was 3.2% (≤ 5 years, 3.8%; 6-11 years, 4.1%; 12-17 years, 1.7%). Of these, 59.1% (≤ 5 years, 66.1%; 6-11 years, 60.1%; 12-17 years, 39.4%), 38.8% (≤ 5 years, 33.9%; 6-11 years, 38.0%; 12-17 years, 53.1%), and 2.0% (≤ 5 years, 0.0%; 6-11 years, 1.9%; 12-17 years, 7.5%) had mild, moderate, and severe AD, respectively. Patients with moderate AD reported greater impacts on HRQoL than patients with mild AD (too few patients with severe AD provided HRQoL data for comparison). Overall, 90.5% patients reported ≥ 1 atopic comorbid condition. The mean (SD) itch, skin pain, and sleep disturbance NRS values were 5.9 (2.4), 5.6 (2.6), and 5.9 (2.3), respectively.Conclusions: These results demonstrate that AD is associated with substantial patient burden in pediatric patients in China.","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"1319-1329"},"PeriodicalIF":3.5000,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12092880/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Dermatology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s13555-025-01403-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/4/17 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: We aimed to estimate the prevalence, severity, and burden of pediatric atopic dermatitis (AD) in China.

Methods: EPI-CARE China was a cross-sectional online survey that assessed AD in the general pediatric populations (aged 0.5‒17 years) between 21 March 2021 and 5 April 2021 in China. Diagnosis of AD prevalence was based on both International Study of Asthma and Allergies in Childhood criteria and self-reported or parent-reported physician confirmation of ever having had AD. Severity (mild, moderate, and severe) in the preceding week was assessed by patient global assessment. Health-related quality of life (HRQoL) was assessed using established dermatology patient-reported outcomes tools (Infant Dermatitis Quality of Life and Children's Dermatology Life Quality Index). Outcomes included type 2 inflammatory comorbidities and itch, skin pain, and sleep disturbance in the previous 24 h (numeric rating scale [NRS]: 0-10 [no symptoms-worst symptoms]), stratified by age group (aged ≤ 5 years, 6-11 years, and 12-17 years).

Results: In 7148 patients, AD prevalence was 3.2% (≤ 5 years, 3.8%; 6-11 years, 4.1%; 12-17 years, 1.7%). Of these, 59.1% (≤ 5 years, 66.1%; 6-11 years, 60.1%; 12-17 years, 39.4%), 38.8% (≤ 5 years, 33.9%; 6-11 years, 38.0%; 12-17 years, 53.1%), and 2.0% (≤ 5 years, 0.0%; 6-11 years, 1.9%; 12-17 years, 7.5%) had mild, moderate, and severe AD, respectively. Patients with moderate AD reported greater impacts on HRQoL than patients with mild AD (too few patients with severe AD provided HRQoL data for comparison). Overall, 90.5% patients reported ≥ 1 atopic comorbid condition. The mean (SD) itch, skin pain, and sleep disturbance NRS values were 5.9 (2.4), 5.6 (2.6), and 5.9 (2.3), respectively.

Conclusions: These results demonstrate that AD is associated with substantial patient burden in pediatric patients in China.

查看原文本刊更多论文

中国儿童特应性皮炎的流行病学和负担。

前言：我们旨在评估中国儿童特应性皮炎（AD）的患病率、严重程度和负担。方法：EPI-CARE中国是一项横断面在线调查，评估2021年3月21日至2021年4月5日期间中国普通儿科人群（0.5-17岁）的AD。阿尔茨海默病患病率的诊断是基于国际儿童哮喘和过敏研究的标准和自我报告或父母报告的医生证实曾经患有阿尔茨海默病。前一周的严重程度（轻度、中度和重度）通过患者总体评估进行评估。健康相关生活质量（HRQoL）采用已建立的皮肤病患者报告结果工具（婴儿皮炎生活质量和儿童皮肤病生活质量指数）进行评估。结果包括过去24小时内2型炎症合并症、瘙痒、皮肤疼痛和睡眠障碍（数值评定量表[NRS]: 0-10[无症状-症状最严重]），按年龄组分层（年龄≤5岁、6-11岁和12-17岁）。结果：7148例患者中，AD患病率为3.2%(≤5年，3.8%；6-11岁，4.1%；12-17年，1.7%)。其中59.1%(≤5年，66.1%；6-11岁，60.1%；12-17岁，39.4%),38.8%(≤5岁，33.9%；6-11岁，38.0%；12-17岁，53.1%),2.0%(≤5岁，0.0%；6-11岁，1.9%；12-17岁（7.5%）分别患有轻度、中度和重度AD。中度AD患者对HRQoL的影响大于轻度AD患者（重度AD患者提供的HRQoL数据太少，无法进行比较）。总体而言，90.5%的患者报告了≥1种特应性合并症。瘙痒、皮肤疼痛和睡眠障碍的平均NRS值（SD）分别为5.9（2.4）、5.6（2.6）和5.9（2.3）。结论：这些结果表明，AD与中国儿科患者的大量患者负担有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Dermatology and Therapy Medicine-Dermatology

CiteScore

6.00

自引率

8.80%

发文量

187

审稿时长

6 weeks

期刊介绍： Dermatology and Therapy is an international, open access, peer-reviewed, rapid publication journal (peer review in 2 weeks, published 3–4 weeks from acceptance). The journal is dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of dermatological therapies. Studies relating to diagnosis, pharmacoeconomics, public health and epidemiology, quality of life, and patient care, management, and education are also encouraged. Areas of focus include, but are not limited to all clinical aspects of dermatology, such as skin pharmacology; skin development and aging; prevention, diagnosis, and management of skin disorders and melanomas; research into dermal structures and pathology; and all areas of aesthetic dermatology, including skin maintenance, dermatological surgery, and lasers. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/case series, trial protocols, and short communications. Dermatology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an International and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. The journal appeals to a global audience and receives submissions from all over the world.